DUBLIN, Sept. 17, 2018 /PRNewswire/ --
The "Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023.
This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials.
The majority of the market will be dominated by microbiome based therapeutics, with an estimate of 90%, compared to 10% in microbiome diagnostics.
This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.
Key Points Covered:
Key Questions Answered:
Key Topics Covered:
Chapter 1 Executive Summary
1.1 Synopsis
1.2 Objective of Report
1.3 Executive Summary
1.4 Key Questions Answered
1.5 Data Sources & Methodology
Chapter 2 Microbiome Overview
2.1 Microbiome Overview
2.2 Human Microbiome in Health and Disease
2.2.1 Cancer
2.2.2 Obesity
2.2.3 Microbiota Metabolism
2.2.3 Type 2 Diabetes Mellitus
2.2.4 Ulcerative Colitis and Crohn's Disease
2.2.5 Clostridium Difficile Infection
2.2.6 Lactose Intolerance
2.2.7 CNS Disorders (gut brain axis)
2.2.8 Dental caries
2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
2.2.10 Skin Diseases
2.2.11 Hyperoxaluria
2.2.12 Urea Cycle Disorder
2.2.13 Celiac Disease
2.2.14 Non-alcoholic Steatohepatitis (NASH)
2.2.15 Hepatic Encephalopathy
2.3 Types of Microbiome therapeutics
2.3.1 Prebiotics
2.3.2 Live BioTherapeutic Agents (Probiotics)
2.3.3 Fecal Microbiota Transplantation (FMT)
2.3.4 Small Molecules
2.4 Advances in Microbiome Research
2.4.1 MetaHIT Consortium
2.4.2 Human Microbiome Project
2.4.3 Functional Metagenomics
2.4.4 Microbiome Metabolomics
2.4.5 Identifying Microbiome Targets - Enterome EB8018 Case Study
2.5 Geographical Variation of Microbiome Composition
Chapter 3 Human Therapeutic and Diagnostic Pipeline Analysis
3.0 Synopsis
3.1 Clostridium Difficile
3.1.1 SER-109 Seres Therapeutics
3.1.2 SER-262 Seres Therapeutics
3.1.3 RBX2660 Rebiotix
3.1.4 VE303 Vedanta Biosciences
3.1.5 IMM-529 Immuron
3.1.6 MET-2 NuBiyota
3.1.7 CP101 Finch Therapeutics
3.1.8 ABI-M101 Assembly Biosciences
3.1.9 CBM-588 Osel
3.1.10 SYN-004 Synthetic Biologics
3.1.11 SYN-006 Synthetic Biologics
3.2 Ulcerative Colitis
3.2.1 FIN-524 Finch Therapeutics
3.2.2 SER-287 Seres Therapeutics
3.2.3 ABI-M201 Assembly Biosciences
3.3 Crohn's Disease
3.3.1 ABI-M301 Assembly Biosciences
3.3.2 Thetanix 4D Pharma
3.4 Inflammatory Bowel Disease
3.4.1 SER-301 Seres Therapeutics
3.4.2 SGM-1019 Second Genome
3.4.3 Blautix 4D Pharma
3.4.4 SG-2-0776 Second Genome
3.4.5 IBD110 - Enterome/AbbVie
3.5 Immuno-Oncology
3.5.1 SER-401 Seres Therapeutics
3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
3.5.3 Colorectal Cancer (CRC) Test - Origin Sciences
3.6 Graft Versus Host Disease
3.6.1 SER-155 Seres Therapeutics
3.7 Urinary Tract Infections
3.7.1 LACTIN-V Osel
3.8 Liver Disease
3.8.1 SGM-1019 Second Genome
3.9 Phenylketoneuria
3.9.1 SYNB1020 Synlogic
3.9.2 SYNB1618 Synlogic
Chapter 4 Market Analysis & Forecast to 2023
4.0 Synopsis
4.1 Market Applications
4.1.1 Clostridium Difficile Infection
4.1.2 Inflammatory Bowel Disease
4.1.3 Ulcerative Colitis
4.1.4 Crohn's Disease
4.1.5 Liver Disease
4.1.6 Immuno-Oncology
4.1.7 Phenylketonuria
4.2 Competitive Landscape
4.3 Market Forecast to 2023
4.3.1 Synopsis
4.3.2 Primary Research, Clinical Trial and Pipeline Trends and Analysis
4.3.3 Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
4.3.4 Geographical Breakdown Analysis and Forecast to 2023
4.3.5 Therapeutic and Diagnostic Submarket Breakdown By Indication
Chapter 5 Market Drivers, Trends & SWOT Analysis
5.1 Market Drivers & Trends
5.2 Market Threats & Challenges
5.3 Market Opportunities
Chapter 6 Investment and Market Deals
6.1 Public and Private Funding in the Microbiome Space
6.2 Current Market Deals
Chapter 7 Venture Capital and The Microbiome
7.0 Synopsis
7.1 How Much Investment Has been Poured into the Microbiome Space in Recent Years?
7.2 What Investment Firms are Interested in the Microbiome Space?
7.3 What Companies are Receiving Funding?
7.4 What Funding Cycles are Emerging in this Space?
Chapter 8 Major Players and Company Profiles
8.1 4D Pharma
8.2 Abbvie
8.3 Allergan
8.4 Assembly Biosciences
8.5 Bristol Myers Squibb
8.6 C3J Therapeutics
8.7 Da Volterra
8.8 Enterome
8.9 Finch Therapeutics
8.10 Immuron
8.11 Matrisys Bioscience
8.12 Merck
8.13 Osel
8.14 Pfizer
8.15 Quorum Innovations
8.16 Rebiotix
8.17 Second Genome
8.18 Seres Therapeutics
8.19 Synlogic
8.20 Synthetic Biologics
8.21 Takeda
8.22 Vedanta Biosciences
For more information about this report visit
https://www.researchandmarkets.com/research/bvh2sk/global_microbiome?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
These press releases may also interest you
|